Rethinking
Brain Health

Space Caps Psychedelics works to improve patient outcomes through our pipeline of novel drug candidates and digital therapeutics.

We strive to deliver on the therapeutic potential of psychedelics and other novel compounds to address unmet patient needs in the fields of psychiatry, addiction, pain and neurology.

Anxiety

21 %
1-year of prevalence anxiety disorders in the US

Pain

50 %
Most US adults live in chronic pains daily

OPIOID USE DISORDER

68630
US deaths from opioid overdose in 2020

AUTISM SPECTRUM DISORDER

$ 461 B
Economic cost of ASD in the US predicted by 2025

Black Friday Sale

Shop Now For A Desired Mind Product
Free Shipping
Over $150
100% Secure

payments

Best Price

Save up 64%

Specialist

Since 2007 till date

Dedicated Us

Support

A Global Leader in Brain Health

Space Caps psychedelics uses industry-leading drug development expertise in its mission to unlock the full therapeutic potential of psychedelics and other novel therapeutic targets.

Play Video

Research & Development Pipeline

Our pipeline offers opportunities across diverse therapeutic areas and mechanisms of action.

Explore Space Cap’s R&D Programs to learn more about the opportunities that exist to advance novel treatments for a wide range of brain health disorders.

We have the right people working for the right reasons.

Our world-class team of drug developers and digital medicine experts was built to advance innovative solutions for the major unmet medical need in brain health disorders.

Mira Halperin Wernli PhD
Executive President
Daniel Carlin
Chief Medical Doctor
Shawn Greenway
Chief Commercial Officer
Mark Lithunberk
Chief Financial Officer
Jen Liao
Principal Accounting Officer
Silver Robert PhD
VP Head of Department